Patents by Inventor TOM M. LAM
TOM M. LAM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240092758Abstract: Provided herein are compounds of formula (I): and pharmaceutically-acceptable salts thereof, where A, W, X, Y and Z are defined in the specification. The compounds of formula (I) and pharmaceutically-acceptable salts thereof are Janus kinase (JAK) inhibitors. Also provided herein are pharmaceutical compositions comprising such compounds; and methods of using such compounds to treat, e.g., inflammatory and fibrotic diseases, including respiratory diseases.Type: ApplicationFiled: June 24, 2022Publication date: March 21, 2024Inventors: Robert Murray MCKINNELL, Tom M. LAM, Cameron SMITH, Philip GERKEN, Paul ALLEGRETTI, Gabrielle Elaine DOLGONOS, Christina OWENS
-
Patent number: 11697648Abstract: The disclosure provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The disclosure also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal inflammatory diseases.Type: GrantFiled: November 24, 2020Date of Patent: July 11, 2023Assignee: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Diana Jin Wang, Anthony Francesco Palermo, Luke Boralsky, Breena Fraga
-
Patent number: 11339160Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal and other inflammatory diseases.Type: GrantFiled: October 23, 2020Date of Patent: May 24, 2022Assignee: Theravance Biopharma R&D IP, LLCInventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Anthony Francesco Palermo
-
Publication number: 20220119369Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: February 22, 2021Publication date: April 21, 2022Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Jerry Nzerem, Marta Dabros, Venkat R. Thalladi, Miroslav Rapta
-
Publication number: 20210188844Abstract: The disclosure provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The disclosure also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal inflammatory diseases.Type: ApplicationFiled: November 24, 2020Publication date: June 24, 2021Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Diana Jin Wang, Anthony Francesco Palermo, Luke Boralsky, Breena Fraga
-
Patent number: 10968205Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: November 19, 2019Date of Patent: April 6, 2021Assignee: Theravance Biopharma R&D IP, LLCInventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Jerry Nzerem, Marta Dabros, Venkat R. Thalladi, Miroslav Rapta
-
Publication number: 20210040085Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal and other inflammatory diseases.Type: ApplicationFiled: October 23, 2020Publication date: February 11, 2021Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Anthony Francesco Palermo
-
Patent number: 10851102Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal and other inflammatory diseases.Type: GrantFiled: January 22, 2020Date of Patent: December 1, 2020Assignee: Theravance Biopharma R&D IP, LLCInventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Anthony Francesco Palermo
-
Publication number: 20200231590Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal and other inflammatory diseases.Type: ApplicationFiled: January 22, 2020Publication date: July 23, 2020Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Anthony Francesco Palermo
-
Publication number: 20200216423Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: November 19, 2019Publication date: July 9, 2020Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: ROBERT MURRAY MCKINNELL, ERIK FENSTER, TOM M. LAM, JERRY NZEREM, MARTA DABROS, VENKAT R. THALLADI, MIROSLAV RAPTA
-
Patent number: 10538513Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: June 28, 2019Date of Patent: January 21, 2020Assignee: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Jerry Nzerem, Marta Dabros, Venkat R. Thalladi, Miroslav Rapta
-
Publication number: 20190315724Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: June 28, 2019Publication date: October 17, 2019Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: ROBERT MURRAY MCKINNELL, ERIK FENSTER, TOM M. LAM, JERRY NZEREM, MARTA DABROS, VENKAT R. THALLADI, MIROSLAV RAPTA
-
Patent number: 10392368Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: July 31, 2018Date of Patent: August 27, 2019Assignee: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Erik Fenster, Tom M. Lam, Mandy Loo, Robert Murray McKinnell, Anthony Francesco Palermo, Diana Jin Wang, Breena Fraga, Jerry Nzerem, Marta Dabros, Venkat R. Thalladi, Miroslav Rapta
-
Publication number: 20190040043Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.Type: ApplicationFiled: July 31, 2018Publication date: February 7, 2019Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: ERIK FENSTER, TOM M. LAM, MANDY LOO, ROBERT MURRAY MCKINNELL, ANTHONY FRANCESCO PALERMO, DIANA JIN WANG, BREENA FRAGA, JERRY NZEREM, MARTA DABROS, VENKAT R. THALLADI, MIROSLAV RAPTA
